Sign in
4

Changes in Ownership

Avalo Therapeutics, Inc. Filed Acc 0001677896-26-000004

Chief Legal Officer sold 75,063 shares at an average $20.17 ($1,513,673)

  • Chief Legal Officer acquired 75,063 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

VARKI PAUL · Chief Legal Officer

Table I: Non-derivative

7 lines
Date Transaction Shares Price Value Owned after D/I
2026-05-06 Exercise or conversion : show line 1 in the form 10b5-1 +62,500 $13.43 $839,375 66,134 D
2026-05-06 Exercise or conversion : show line 2 in the form 10b5-1 +12,563 $8.04 $101,007 78,697 D
2026-05-06 Sale : show line 3 in the form 10b5-1 −37,375 $18.91 $706,836 41,322 D
2026-05-06 Sale : show line 4 in the form 10b5-1 −5,196 $19.78 $102,783 36,126 D
2026-05-06 Sale : show line 5 in the form 10b5-1 −22,839 $21.22 $484,541 13,287 D
2026-05-06 Sale : show line 6 in the form 10b5-1 −9,253 $22.70 $210,029 4,034 D
2026-05-06 Sale : show line 7 in the form 10b5-1 −400 $23.71 $9,484 3,634 D
Open-market sales · 75,063 sh · avg $20.17 · $1,513,673

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2026-05-06 Exercise or conversion : show line 8 in the form 10b5-1 Stock Option (Right to Buy) −62,500 87,500 D
2026-05-06 Exercise or conversion : show line 9 in the form 10b5-1 Stock Option (Right to Buy) −12,563 87,437 D
Loading xslF345X06/form4-05072026_080504.xml…